Search results for "breast neoplasms"

showing 10 items of 804 documents

Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemothera…

2016

Abstract Background The recommendation for adjuvant dose-dense chemotherapy in high risk primary breast cancer is heterogeneous among guidelines. Understanding the impact on QoL is thereby a crucial factor, especially if the benefit is potentially low. This study aims to assess QoL as a secondary outcome in the prospective randomized multi-center ADEBAR trial. Methods QoL was assessed at baseline (t1), before cycle 4 FEC and cycle 5 EC-DOC (t2), 4 weeks after chemotherapy (t3) and 6 weeks after radiation (t4) using the European Organization for Research and Treatment for Cancer (EORTC) Quality of Life Core Questionnaire (QLQ-C30) and the Breast Cancer-Specific Module (QLQ-BR23). Results 130…

0301 basic medicineOncologyAdultmedicine.medical_specialtyTime FactorsAdolescentNauseamedicine.medical_treatmentBreast NeoplasmsDocetaxelDrug Administration Schedule03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerQuality of lifeInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesProspective cohort studyCyclophosphamideAgedEpirubicinChemotherapybusiness.industryGeneral MedicineMiddle Agedmedicine.diseasehumanitiesSurgery030104 developmental biologyTreatment OutcomeDocetaxelFluorouracilChemotherapy Adjuvant030220 oncology & carcinogenesisQuality of LifeSurgeryFemaleTaxoidsFluorouracilmedicine.symptombusinessmedicine.drugEpirubicinBreast (Edinburgh, Scotland)
researchProduct

TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.

2018

Abstract Triple-negative breast cancer (TNBC) is an aggressive disease lacking targeted therapy. In this study, we developed a CAR T cell–based immunotherapeutic strategy to target TEM8, a marker initially defined on endothelial cells in colon tumors that was discovered recently to be upregulated in TNBC. CAR T cells were developed that upon specific recognition of TEM8 secreted immunostimulatory cytokines and killed tumor endothelial cells as well as TEM8-positive TNBC cells. Notably, the TEM8 CAR T cells targeted breast cancer stem–like cells, offsetting the formation of mammospheres relative to nontransduced T cells. Adoptive transfer of TEM8 CAR T cells induced regression of established…

0301 basic medicineOncologyCancer ResearchAdoptive cell transfermedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentT-LymphocytesCell- and Tissue-Based TherapyReceptors Antigen T-CellApoptosisReceptors Cell SurfaceTriple Negative Breast NeoplasmsTargeted therapy03 medical and health sciencesMice0302 clinical medicineBreast cancerAntigenInternal medicineBiomarkers TumorTumor Cells CulturedMedicineAnimalsHumansTriple-negative breast cancerCell Proliferationbusiness.industryMicrofilament ProteinsCancerImmunotherapyTriple Negative Breast Neoplasmsmedicine.diseasePrognosisXenograft Model Antitumor AssaysNeoplasm ProteinsSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisCase-Control StudiesFemaleImmunotherapybusinessFollow-Up StudiesCancer research
researchProduct

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

2020

AbstractBackgroundHER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and trastuzumab emtansine (T-DM1) in second-line. Thereby, evidence of T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, with data from some retrospective reports suggesting lower activity. The purpose of the present study is to investigate T-DM1 efficacy in pertuzumab-pretreated and pertuzumab naïve HER2 positive ABC patients. We also aimed to provide evidence on the exposure to d…

0301 basic medicineOncologyCancer ResearchReceptor ErbB-2ApoptosisAdo-Trastuzumab EmtansineSettore MED/06chemistry.chemical_compound0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturedskin and connective tissue diseasesAged 80 and overMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisGene Expression Regulation NeoplasticSurvival RateOncology030220 oncology & carcinogenesisFemalePertuzumabmedicine.drugT-DM1 efficacymusculoskeletal diseasesAdultmedicine.medical_specialtyHER2+ breast cancer; Trastuzumab/pertuzumab blockade; T-DM1 efficacyBreast NeoplasmsAntibodies Monoclonal Humanizedlcsh:RC254-28203 medical and health sciencesSettore MED/04 - PATOLOGIA GENERALEInternal medicinemedicineBiomarkers TumorHumansneoplasmsAgedCell ProliferationRetrospective StudiesHER2+ breast cancer; T-DM1 efficacy; Trastuzumab/pertuzumab blockadeTaxanebusiness.industryResearchCancerHER2+ breast cancerTrastuzumabmedicine.diseaseTrastuzumab/pertuzumab blockadeBlockadeLog-rank test030104 developmental biologychemistryTrastuzumab emtansineCancer cellbusiness
researchProduct

PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival.

2017

Background: PTTG1-interacting protein (PTTG1IP) is an oncogenic protein, which participates in metaphase-anaphase transition of the cell cycle through activation of securin (PTTG1). PTTG1IP promotes the shift of securin from the cell cytoplasm to the nucleus, allowing the interaction between separase and securin. PTTG1IP overexpression has been previously observed in malignant disease, e.g. in breast carcinoma. However, the prognostic value of PTTG1IP in breast carcinoma patients has not previously been revealed. Methods: A total of 497 breast carcinoma patients with up to 22-year follow-up were analysed for PTTG1IP and securin immunoexpression. The results were evaluated for correlations w…

0301 basic medicineOncologyCancer ResearchTriple Negative Breast NeoplasmsKaplan-Meier EstimatePBF0302 clinical medicineBreast cancerSurgical oncologyRisk FactorsAged 80 and overrintasyöpäPTTG1 interacting proteinIntracellular Signaling Peptides and ProteinsCell cycleMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisImmunohistochemistrySecurinsyöpägeenitOncologySecurin030220 oncology & carcinogenesisImmunohistochemistryFemaleSeparaseBreast carcinomaResearch ArticleAdultmedicine.medical_specialtyPTTG1IPBreast Neoplasmslcsh:RC254-282immunohistokemia03 medical and health sciencesBreast cancerInternal medicineGeneticsmedicineBiomarkers TumorHumansAgedbusiness.industryMembrane Proteinsmedicine.disease030104 developmental biologyMultivariate AnalysisCancer researchprognosisproteiinitbusinessBMC cancer
researchProduct

SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer

2020

New treatment strategies such as immune checkpoint inhibitors and oncolytic viruses are opening new possibilities in cancer therapy. Preliminary results in melanoma and other tumors showed that the combination of talimogene laherparepvec with an anti-PD-1/PD-L1 or anti-CTLA4 has greater efficacy than either therapy alone, without additional safety concerns beyond those expected for each agent. The presence of residual cancer after neoadjuvant chemotherapy in early breast cancer patients is an unmet medical need. SOLTI-1503 PROMETEO is a window of opportunity trial, which evaluates the combination of talimogene laherparepvec in combination with atezolizumab in women with operable HER2-negati…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBreast NeoplasmsHerpesvirus 1 HumanAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineBreast cancerClinical ProtocolsAtezolizumabInternal medicineClinical endpointHumansMedicineImmune Checkpoint InhibitorsTriple-negative breast cancerNeoplasm StagingOncolytic VirotherapyBiological ProductsClinical Trials as Topicbusiness.industryMelanomaGeneral MedicineImmune Checkpoint Proteinsmedicine.diseaseCombined Modality TherapyOncolytic virusClinical trial030104 developmental biologyOncologyResearch Design030220 oncology & carcinogenesisFemalebusinessTalimogene laherparepvecFuture Oncology
researchProduct

Ki-67 Expression as a Factor Predicting Recurrence of Ductal Carcinoma In Situ of the Breast: A Systematic Review and Meta-Analysis

2018

Abstract Background Ki-67 is a marker of proliferating cells; in this meta-analysis we aimed to examine whether Ki-67 expression can predict recurrence rates of breast ductal carcinoma in situ (DCIS). Materials and Methods This systematic review and meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible articles were sought in MEDLINE up to April 30, 2017. Random effects (DerSimonian–Laird) models were used for the calculation of pooled relative risk (RR) estimates; meta-regression analysis was also performed. Separate analyses were performed according to Ki-67 expression cutoff levels, invasiveness of recurrence,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBreast NeoplasmsRisk Assessment03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemedicineHumansMeta-regressionBreastMastectomybiologybusiness.industryDuctal carcinomaPrognosismedicine.diseaseConfidence intervalCarcinoma Intraductal NoninfiltratingKi-67 Antigen030104 developmental biologyOncology030220 oncology & carcinogenesisRelative riskMeta-analysisKi-67biology.proteinFemaleRadiotherapy AdjuvantNeoplasm Recurrence LocalbusinessCohort studyClinical Breast Cancer
researchProduct

Prospective validation of a blood-based 9-miRNA profile for early detection of breast cancer in a cohort of women examined by clinical mammography

2016

Mammography is the predominant screening method for early detection of breast cancer, but has limitations and could be rendered more accurate by combination with a blood-based biomarker profile. Circulating microRNAs (miRNAs) are increasingly recognized as strong biomarkers, and we previously developed a 9-miRNA profile using serum and LNA-based qPCR that effectively stratified patients with early stage breast cancer vs. healthy women. To further develop the test into routine clinical practice, we collected serum of women examined by clinical mammography (N = 197) according to standard operational procedures (SOPs) of the Danish Cancer Biobank. The performance of the circulating 9-miRNA pro…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyEarly detectionBreast NeoplasmsCancer BiobankDisease03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemicroRNABiomarkers TumorGeneticsmedicineHumansMammographyBreastProspective StudiesStage (cooking)Research ArticlesAgedGynecologymedicine.diagnostic_testbusiness.industryGene Expression ProfilingGeneral MedicineMiddle AgedPrognosismedicine.diseaseMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisCohortMolecular MedicineBiomarker (medicine)FemaleSample collectionbusinessMammography
researchProduct

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer

2021

BackgroundThe prognosis of early breast cancer is linked to clinic-pathological stage and the molecular characteristics of intrinsic tumor cells. In some patients, the amount and quality of tumor-infiltrating immune cells appear to affect long term outcome. We aimed to propose a new tool to estimate immune infiltrate, and link these factors to patient prognosis according to breast cancer molecular subtypes.MethodsWe performed in silico analyses in more than 2800 early breast cancer transcriptomes with corresponding clinical annotations. We first developed a new gene expression deconvolution algorithm that accurately estimates the quantity of immune cell populations (tumor immune contexture,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMyeloid2435In silicoImmunologyCellbiostatisticsBreast NeoplasmsTranscriptome03 medical and health sciences0302 clinical medicineBreast cancerImmune systemLymphocytes Tumor-InfiltratingInternal medicinemedicineBiomarkers TumorImmunology and Allergytumor microenvironmentHumans1506Stage (cooking)RC254-282Neoplasm StagingPharmacologyClinical/Translational Cancer ImmunotherapyTumor microenvironmentbusiness.industryGene Expression ProfilingNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosisSurvival AnalysisGene Expression Regulation Neoplastic030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesistumor biomarkersMolecular MedicineFemalebusinessAlgorithmsUnsupervised Machine LearningJournal for Immunotherapy of Cancer
researchProduct

Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores

2021

Several scores have been developed in order to estimate the prognosis of patients with brain metastases (BM) by objective criteria. The aim of this analysis was to validate all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer (BC) patients with BM in the Brain Metastases in the German Breast Cancer (BMBC) registry. The median age at diagnosis of BM was 57 years. All in all, 22.3% of patients (n = 197) had triple-negative, 33.4% (n = 295) luminal A like, 25.1% (n = 221) luminal B/HER2-enriched like and 19.2% (n = 169) HER2 positive like BC. Age ≥60 years, evidence of extracranial metastases (ECM), higher number of BM, triple-negative subtype and l…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyNeoplasm metastasisAge at diagnosisPrognoseDiagnostic accuracylcsh:RC254-282ArticleMetastasis03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicinebrain metastasesOverall survivalBrustkrebsMedicineddc:610HirnmetastaseUnivariate analysisbusiness.industryBrainLuminal aLuminal blcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosis030104 developmental biologyOncology030220 oncology & carcinogenesisBreast; CancerPrognostic groupBreast neoplasmsbusinessDDC 610 / Medicine & healthprognostic scoresCancers
researchProduct

Is There an Association between β-Carotene and Breast Cancer? A Systematic Review on Breast Cancer Risk

2020

It is suspected that diet influences the risk of developing breast cancer. Several β-carotenoids have been inversely associated with breast cancer risk, but association by type of tumor and participant characteristics remain nuclear. The objective of this review of epidemiological studies is to investigate the relationship between β-carotenoids and breast cancer. This review covers the 2014-2020 period and was carried out using the PubMed and EMBASE databases. Only epidemiological studies carried out on β-carotenoids and breast cancer were included. The initial keyword search yielded 1559 results and finally a total of 28 studies were included. The quality of the articles and the risk of bi…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMEDLINEMedicine (miscellaneous)Breast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerRisk FactorsInternal medicineEpidemiologymedicineHumans030109 nutrition & dieteticsNutrition and DieteticsKeyword searchbusiness.industryDietary intakeCarotenebeta Carotenemedicine.diseaseCarotenoidsDietOncology030220 oncology & carcinogenesisFemalebusinessNutrition and Cancer
researchProduct